+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Treponema Pallidum Tests (In Vitro Diagnostics) - Global Market Analysis and Forecast Model

  • Report

  • November 2018
  • Region: Global
  • GlobalData
  • ID: 4720170
Treponema Pallidum Tests (In Vitro Diagnostics) - Global Market Analysis and Forecast Model

Summary

Treponema Pallidum Tests (In Vitro Diagnostics) - Global Market Analysis and Forecast Model is built to visualize quantitative market trends within In Vitro Diagnostics Tests Analysis and Forecast Model therapeutic area.

Incidence of Syphilis is increasing in most countries and geographical regions. This is predicted to lead to a higher number of suspected infection cases being tested as well as improved disease awareness and the implementation of new screening initiatives. However, disease incidence is not the only factor influencing the Treponema Pallidum or Syphilis Tests market. Sales of these devices are also heavily impacted by fluctuations in the number of pregnant women, semen donations, whole blood donations, and source plasma donations.

While source plasma donations are expected to increase during the forecast period, live birth rates and voluntary whole blood donations are decreasing in many countries and this is expected to cause a decline in some North American, European, APAC, and Middle East and African markets. Additionally, Enzyme Immuno Assay (EIA) tests are predicted to be more frequently utilized in numerous countries. This switch in device usage is expected to bolster growth of the Syphilis Tests market overall, as EIA tests tend to be more expensive that some of their device counterparts.

Each of the covered 39 country’s color-coded and fully-sourced market models are equipped with epidemiology based indications with procedure volumes. To increase the data transparency, the interactive excel deliverable covers installed base, new sales volumes, product usage, average selling prices, market size and company share/rank analysis (wherever available). Moreover, analyst comments with qualitative insight offer context for quantitative data.

Key Inclusions

Currently marketed Treponema Pallidum Tests and evolving competitive landscape -
  • Insightful review of the key industry trends.

  • Annualized total Treponema Pallidum Tests market revenue by segment and market outlooks from 2015-2028.

  • Granular data on total procedures, units, average selling prices and market values by segment.


Global, Regional and Country level market specific insights -
  • Qualitative market specific information is available with global trends further broken down into regional trends. In addition analysts provide unique country specific insights on the market.

  • SWOT analysis for Treponema Pallidum Tests market.

  • Competitive dynamics insights and trends provided for Treponema Pallidum Tests market.


Drive the understanding of the market by getting the veritable big picture including an overview of the healthcare system. In addition the Market Access segment allows you to delve deeper into market dynamics with information on reimbursement policies and the regulatory landscape.
  • Country specific overview of the healthcare system.

  • Country specific reimbursement policies.

  • Country specific medtech regulatory landscape.


Robust methodologies and sources enable the model to provide extensive and accurate overview of the market. Demand and supply-side primary sources are integrated within the syndicated models, including Key Opinion Leaders. In addition, real world data sources are leveraged to determine market trends; these include government procedure databases, hospital purchasing databases, and proprietary online databases.

Companies covered: Becton Dickinson and Co, Abbott Laboratories, Siemens Healthcare GmbH, Bio-Rad Laboratories Inc., Miraca Holdings Inc. (Fujirebio Inc.), Trinity Biotech Plc, Arlington Scientific, Inc., Roche Diagnostics International Ltd, Tecan Group Ltd (IBL International GmbH), Tulip Diagnostics (P) Ltd (Qualpro Diagnostics), Cardinal Health Inc., BioMerieux Inc., DiaSorin S.p.A., Omega Diagnostics Group Plc, Rapid Labs Ltd, Deben Diagnostics Ltd, Lorne Laboratories Ltd, Werfen Life Group SAU (Biokit S.A.), Sekisui Medical Co. Ltd.

Countries covered: United States, United Kingdom, Germany, France, Italy, Spain, Brazil, China, India, Russia, Japan, Australia, Canada, Mexico, South Korea, Denmark, Ireland, Netherlands, New Zealand, South Africa, Sweden, Switzerland, Austria, Belgium, Finland, Israel, Norway, Poland, Portugal, Taiwan, Czech Republic, Greece, Hungary, Turkey, Egypt, Saudi Arabia, United Arab Emirates, Argentina and Chile.

Scope

This Market Model gives important, expert insight you won’t find in any other source. The model illustrates qualitative and quantitative trends within the specified market. This model is required reading for -
  • CMO executives who must have deep understanding of the Treponema Pallidum Test marketplace to make strategic planning and investment decisions.

  • Sourcing and procurement executives who must understand crucial components of the supply base in order to make decisions about supplier selection and management.

  • Private equity investors that need a deeper understanding of the market to identify and value potential investment targets.


Reasons to Buy

The model will enable you to -
  • Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.

  • Develop business strategies by understanding the trends shaping and driving Treponema Pallidum market.

  • Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the Treponema Pallidum market in the future.

  • Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the company share of market leaders.

  • Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.

  • Track device sales in the global and country-specific Treponema Pallidum market from 2015-2028.

  • Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • Becton Dickinson and Co

  • Abbott Laboratories

  • Siemens Healthcare GmbH

  • Bio-Rad Laboratories Inc.

  • Miraca Holdings Inc. (Fujirebio Inc.)

  • Trinity Biotech Plc

  • Arlington Scientific Inc.

  • Roche Diagnostics International Ltd

  • Tecan Group Ltd